CN115397838A - 溶瘤病毒样囊泡的组合物和使用方法 - Google Patents

溶瘤病毒样囊泡的组合物和使用方法 Download PDF

Info

Publication number
CN115397838A
CN115397838A CN202180020228.5A CN202180020228A CN115397838A CN 115397838 A CN115397838 A CN 115397838A CN 202180020228 A CN202180020228 A CN 202180020228A CN 115397838 A CN115397838 A CN 115397838A
Authority
CN
China
Prior art keywords
sequence
leu
val
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180020228.5A
Other languages
English (en)
Chinese (zh)
Inventor
B·阿尔玛西亚
V·纳卡尔
马先勇
B·R·玛迪娜
王克鹏
T·亚罗温斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carogan
Original Assignee
Carogan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carogan filed Critical Carogan
Publication of CN115397838A publication Critical patent/CN115397838A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20244—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN202180020228.5A 2020-01-10 2021-01-08 溶瘤病毒样囊泡的组合物和使用方法 Pending CN115397838A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959435P 2020-01-10 2020-01-10
US62/959,435 2020-01-10
PCT/US2021/012834 WO2021142366A1 (en) 2020-01-10 2021-01-08 Compositions and methods of use of oncolytic virus like vesicles

Publications (1)

Publication Number Publication Date
CN115397838A true CN115397838A (zh) 2022-11-25

Family

ID=74595378

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020228.5A Pending CN115397838A (zh) 2020-01-10 2021-01-08 溶瘤病毒样囊泡的组合物和使用方法

Country Status (5)

Country Link
US (1) US12577585B2 (https=)
EP (1) EP4087858A1 (https=)
JP (1) JP2023509966A (https=)
CN (1) CN115397838A (https=)
WO (1) WO2021142366A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024213051A1 (zh) * 2023-04-11 2024-10-17 浙江自贸区红岸基地生物科技有限公司 一种saRNA递送系统及其制备方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4460564A4 (en) * 2022-01-08 2026-02-11 Carogen Corp MULTI-ANTIGEN THERAPEUTIC VACCINES TO TREAT OR PREVENT CHRONIC HEPATITIS B VIRUS INFECTION
JP2025508866A (ja) * 2022-02-22 2025-04-10 ヴァイロ バイオ インク． 腫瘍溶解性ウイルスおよび使用方法
CN119110727A (zh) * 2022-02-22 2024-12-10 卡罗根公司 用于感染性疾病和癌症免疫疗法应用的多功能病毒样囊泡(vlv)平台
US20260034208A1 (en) * 2022-07-26 2026-02-05 Yale University Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
IL320318A (en) * 2022-10-19 2025-06-01 Kalivir Immunotherapeutics Inc Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof
WO2024119388A1 (zh) * 2022-12-07 2024-06-13 上海鑫湾生物科技有限公司 一种用于共表达多种目的基因的构建体及其用途
WO2025208054A1 (en) * 2024-03-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Recombinant rhabdovirus encoding interleukin-12 (il-12)
CN120733012A (zh) * 2024-08-20 2025-10-03 浙江大学 基于mRNA及蛋白编码的肿瘤药物、制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
CN106459997A (zh) * 2014-05-16 2017-02-22 耶鲁大学 用于疫苗应用的高效价病毒样囊泡的进化
WO2019057974A1 (en) * 2017-09-22 2019-03-28 Centre National De La Recherche Scientifique (Cnrs) GLYCOPROTEIN MUTATED FROM VESICULAR STOMATITIS VIRUS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
FR2862982B1 (fr) * 2003-12-02 2006-04-28 Genethon Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale.
ES2746960T3 (es) * 2006-09-12 2020-03-09 Alphavax Inc Partículas de replicón de alfavirus que codifican IL-12 como adyuvantes inmunológicos
GB2460265A (en) * 2008-05-23 2009-11-25 Univ Dublin City Detection assembly
AU2015259470A1 (en) 2014-05-16 2016-11-10 Yale University Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
WO2017167317A1 (es) 2016-03-31 2017-10-05 Centro De Ingenieria Genetica Y Biotecnologia Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
JP2019527737A (ja) * 2016-08-09 2019-10-03 アルケヤール， アルモハナッドＡＬＫＡＹＹＡＬ， Ａｌｍｏｈａｎａｄ Ｉｌ１２を発現する腫瘍溶解性ラブドウイルス

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
CN106459997A (zh) * 2014-05-16 2017-02-22 耶鲁大学 用于疫苗应用的高效价病毒样囊泡的进化
WO2019057974A1 (en) * 2017-09-22 2019-03-28 Centre National De La Recherche Scientifique (Cnrs) GLYCOPROTEIN MUTATED FROM VESICULAR STOMATITIS VIRUS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAN JIA等: "Pseudo-typed Semliki Forest virus delivers EGFP into neurons", JOURNAL OF NEUROVIROLOGY, vol. 23, no. 2, 13 October 2016 (2016-10-13), pages 205 - 215, XP036182589, DOI: 10.1007/s13365-016-0486-8 *
TRACY D. REYNOLDS等: "Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection", JOURNAL OF VIROLOGY, vol. 89, no. 20, 5 August 2015 (2015-08-05), pages 10407 - 10415 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024213051A1 (zh) * 2023-04-11 2024-10-17 浙江自贸区红岸基地生物科技有限公司 一种saRNA递送系统及其制备方法和应用

Also Published As

Publication number Publication date
JP2023509966A (ja) 2023-03-10
US12577585B2 (en) 2026-03-17
WO2021142366A1 (en) 2021-07-15
EP4087858A1 (en) 2022-11-16
US20230063041A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US12577585B2 (en) Compositions and methods of use of oncolytic virus like vesicles
FI118011B (fi) Menetelmä replikaatiokyvyn suhteen puutteellisen yhdistelmä-DNA-adenoviruksen tuottamiseksi
US10435712B2 (en) Evolution of high-titer virus-like vesicles for vaccine applications
CN112584849A (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
JP2021045152A (ja) 癌を治療するための治療用組成物及び使用方法
WO2018171103A1 (zh) 可编程的溶瘤病毒疫苗系统及其应用
CN108025054B (zh) 用于治疗和/或预防肿瘤的沙粒病毒和用于制备具有（改善的）肿瘤消退性能的沙粒病毒的方法
WO2013018778A1 (ja) ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
CN112739359A (zh) Apmv及其用于治疗癌症的用途
EP4252852A2 (en) Methods and materials for treating cancer
US12544433B2 (en) Melanoma canine vaccine compositions and methods of use thereof
CN105031630A (zh) 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法
CN110563841A (zh) 一种人源化抗Grb2单克隆抗体、及其制备方法和应用
CN116802282A (zh) 经修饰的基孔肯雅病毒和辛德毕斯病毒及其用途
CN110845621A (zh) 一种靶向egfr和cd19双靶点的嵌合抗原受体方法
CN113637695B (zh) 靶向刺激体液免疫和细胞免疫的新冠病毒mRNA疫苗
Davidoff et al. Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model
US20260034208A1 (en) Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
CN114657150A (zh) 用于改善免疫疗法的重组溶瘤腺病毒及其应用
CN109419818B (zh) 一种用于治疗肿瘤的埃可病毒
CN1517437B (zh) 特异性治疗肿瘤或胞内感染的疫苗及应用
CN120590547B (zh) 通用型mRNA肿瘤疫苗及其制备方法和用途
CN115161293B (zh) 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用
JP2010521460A (ja) 癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制
CN118813708A (zh) 双靶点溶瘤腺病毒载体及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination